10-Q: Skinvisible Inc. Reports First Quarter 2024 Results, Cites Ongoing Concerns

Skinvisible Inc. reports a net loss of $290,372 for the first quarter of 2024, with ongoing concerns about its ability to continue as a going concern.

Summary

• Skinvisible Inc. reported a net loss of $290,372 for the quarter ended March 31, 2024, compared to a net loss of $1,515,056 for the same period in 2023.
• The company's revenue remained consistent at $5,000 for both periods.
• Operating expenses decreased slightly to $128,184 from $132,904 year-over-year.
• The company's total assets were $153,403, with total liabilities of $9,466,818, resulting in a stockholders' deficit of $9,313,415.
• Skinvisible has accumulated net losses of $39,670,860 since its inception and requires additional capital to continue operations.
• Management has expressed substantial doubt about the company's ability to continue as a going concern within one year.
• The company plans to seek additional funding through licensing and debt or equity financing.
• The company has identified material weaknesses in its internal controls over financial reporting.

Sentiment

Score: 2

Explanation: The document expresses significant concerns about the company's financial health, going concern status, and internal controls, leading to a very negative sentiment.

Positives

• The net loss decreased significantly year-over-year, from $1,515,056 to $290,372.
• Operating expenses saw a slight decrease from $132,904 to $128,184.
• There was a positive cash flow from financing activities of $19,500 in Q1 2024, compared to no cash flow in Q1 2023.
• Quoin's clinical trials for product formulations containing Invisicare targeting Netherton Syndrome have shown positive initial data and a clean safety profile.
• Quoin received FDA clearance to recruit teen subjects into both ongoing Netherton Syndrome clinical studies.

Negatives

• The company has a significant working capital deficit of $4,063,726.
• Total liabilities of $9,466,818 far exceed total assets of $153,403.
• The company has accumulated net losses of $39,670,860 since its inception.
• Management has expressed substantial doubt about the company's ability to continue as a going concern.
• There are material weaknesses in internal control over financial reporting.
• The company's revenue remains very low at $5,000 for the quarter.

Risks

• The company's ability to continue as a going concern is in doubt due to significant accumulated losses and a lack of sufficient capital.
• The company's reliance on licensing and future financing is uncertain.
• Material weaknesses in internal controls over financial reporting could lead to misstatements in financial reports.
• The company faces risks related to its operations, business plan, and strategy.
• There are risks related to intellectual property rights and potential infringement claims.
• The company is subject to competition and cybersecurity concerns.

Future Outlook

The company plans to seek additional funding through licensing and debt or equity financing to continue operations, but there is no assurance that they will be successful.

Management Comments

• Management believes the opportunity to license products continues to be a viable model.
• Management has expressed substantial doubt about the company's ability to continue as a going concern within one year.
• Management plans to take steps to enhance and improve the design of internal controls over financial reporting.

Industry Context

The company operates in the pharmaceutical, over-the-counter, personal skincare, and cosmetic arenas, targeting an estimated $80 billion global skincare and dermatology market and a $30 billion global over-the-counter market. The company's business model is to out-license its patented products to established manufacturers and marketers.

Comparison to Industry Standards

• Skinvisible's revenue of $5,000 for the quarter is significantly lower than most publicly traded pharmaceutical or skincare companies.
• The company's substantial net losses and negative equity are not typical for established companies in the industry.
• The company's reliance on licensing revenue and its going concern issues are not common among larger, more stable competitors.
• The company's focus on a patented polymer delivery system is a niche area within the broader skincare and pharmaceutical market, making direct comparisons difficult.
• Companies like Johnson & Johnson, Pfizer, and L'Oreal have significantly larger revenues, profits, and market capitalization, highlighting the vast difference in scale.

Corporate Governance

Related Party Transactions

• During the three months ended March 31, 2024, the Company repaid $3,000 in advances due to related parties.
• As of March 31, 2024, the Company had amounts due to related parties of $3,000.
• On January 31, 2023, the Company renegotiated accrued salaries, vacation, and outstanding convertible notes for its two officers, converting them to promissory notes convertible into common stock with a warrant feature.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern issues.
• Employees may be impacted by potential cost-cutting measures or the company's inability to continue operations.
• Customers and suppliers may be affected by the company's uncertain future.
• Creditors face the risk of not being repaid due to the company's financial difficulties.

Next Steps

• The company plans to file a US patent application for the delivery of weight loss actives.
• The company plans to seek additional financing through licensing and debt or equity financing.
• The company plans to implement changes to remediate material weaknesses in internal control over financial reporting.

Key Dates

Keywords

Invisicare, licensing, pharmaceutical, dermatology, polymer delivery system, net loss, financial statements, going concern, internal controls, Netherton Syndrome